ATNM-400 Targets B7-H3 and Is Being Studied in a Phase 1 Clinical Trial in South Africa

Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) is expanding its radiotherapeutic platform beyond hematologic cancers with ATNM-400, a next-generation candidate designed to deliver targeted radiation against B7-H3, an immune-checkpoint molecule highly expressed across multiple solid tumors. B7-H3 overexpression is linked to tumor aggressiveness, immune evasion, and treatment resistance, making it an increasingly important target. By pairing this biology with its radiotherapy expertise, Actinium Pharmaceuticals is positioning ATNM-400 to address large and persistent unmet needs in solid tumors.

Phase 1 Clinical Evaluation in South Africa

ATNM-400 is now being evaluated in a Phase 1 clinical trial in South Africa. The study is designed to assess safety, biodistribution, and early signs of activity in patients with advanced, B7-H3-expressing solid tumors. This work represents a key milestone for Actinium Pharmaceuticals as it advances into solid-tumor radiotherapy and generates the foundational clinical data needed to guide dose selection and future expansion.

Relevance to Breast Cancer

Recent communications from ATNM emphasize the need for precision therapies in aggressive or treatment-resistant breast cancers. B7-H3 is commonly overexpressed in breast tumors-including hard-to-treat subtypes-and is associated with poorer outcomes. ATNM-400's mechanism is directly aligned with this challenge: targeted delivery of potent radiation to B7-H3-positive tumors while sparing healthy tissue. This creates a strategic fit between the biology of B7-H3 in breast cancer and the company's radiotherapy platform.

Application in Non-Small Cell Lung Cancer

Actinium Pharmaceuticals has also highlighted similar hurdles in non-small cell lung cancer, where relapse rates remain high and effective late-line therapies are limited. B7-H3 expression is elevated in a large proportion of NSCLC cases and contributes to immune escape and reduced treatment responsiveness. ATNM-400's targeted radiotherapy approach has the potential to address these gaps, offering a differentiated mechanism suited to tumors that fail standard therapies.

Building a Solid-Tumor Radiotherapy Pipeline

By combining a broadly expressed solid-tumor antigen with its established radiotherapeutic platform, Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) is taking its first major step into solid tumors. The Phase 1 South Africa trial serves as the gateway to a pipeline that could expand across multiple high-burden indications. If clinical data validate the preclinical rationale, ATNM-400 could become the foundation of a broader B7-H3-directed radiotherapy strategy spanning breast cancer, NSCLC, and other solid malignancies.

Disclaimers: RazorPitch Inc. "RazorPitch" is not operated by a licensed broker, a dealer, or a registered investment adviser. This content is for informational purposes only and is not intended to be investment advice. The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions, or future events or performance are not statements of historical fact may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements indicating certain actions & quote; may, could, or might occur. Understand there is no guarantee past performance will be indicative of future results. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investors investment may be lost or impaired due to the speculative nature of the companies profiled. RazorPitch has been retained and compensated by Awareness Consulting to assist in the production and distribution of content related to ANTM. RazorPitch is responsible for the production and distribution of this content. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. This content is for informational purposes only, you should not construe any such information or other material as legal, tax, investment, financial, or other advice. Nothing contained in this article constitutes a solicitation, recommendation, endorsement, or offer by RazorPitch or any third party service provider to buy or sell any securities or other financial instruments. All content in this article is information of a general nature and does not address the circumstances of any particular individual or entity. Nothing in this article constitutes professional and/or financial advice, nor does any information in the article constitute a comprehensive or complete statement of the matters discussed or the law relating thereto. RazorPitch is not a fiduciary by virtue of any persons use of or access to this content.

Media Contact
Company Name: RazorPitch
Contact Person: Mark McKelvie
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=atnm400-targets-b7h3-and-is-being-studied-in-a-phase-1-clinical-trial-in-south-africa]
City: NAPLES
State: Florida
Country: United States
Website: https://razorpitch.com/

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.